Product Description
AXL, also known as UFO, ARK, or Tyro7, is a member of the receptor tyrosine kinase (RTK) family belonging to the TAM (Tyro3-AXL-Mer) subfamily, which plays a pivotal role in cell survival, proliferation, migration, and immune regulation. AXL binds with high affinity to its ligand, growth arrest-specific protein 6 (Gas6), leading to activation of downstream signaling pathways such as PI3K/AKT, MAPK, and NF-κB. Beyond its essential physiological functions in tissue homeostasis and immune suppression, dysregulation of AXL signaling—including overexpression, gene amplification, and ligand-dependent activation—is closely associated with tumor metastasis, drug resistance (particularly to targeted therapies and chemotherapies), and immune evasion in various cancers, such as lung, breast, and pancreatic cancer. These features have established AXL as a highly validated target for cancer therapy and drug discovery.
Screeningbio’s AXL Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying AXL kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: AXL catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the AXL kinase.
Data